We can’t show the full text here under this license. Use the link below to read it at the source.
GLP‐1RA comparative effectiveness against dementia onset relative to other antidiabetic medications in a large, multi‐site cohort of patients with type 2 diabetes
GLP-1 receptor agonists and their link to dementia risk compared to other diabetes medicines in a large group of type 2 diabetes patients
AI simplified
Abstract
In a cohort of diabetes patients aged ≥ 60 years, GLP-1 receptor agonists (GLP-1RAs) are associated with a 0.016 lower risk of dementia diagnosis compared to sulfonylureas.
- Sustained exposure to GLP-1RAs does not significantly differ in dementia risk when compared to sodium-glucose cotransporter 2 inhibitors (SGLT2i).
- GLP-1RAs are linked to a reduced risk of dementia diagnosis compared to dipeptidyl peptidase 4 inhibitors () with an adjusted risk difference of -0.013.
- The findings suggest a modest risk reduction for dementia with GLP-1RAs versus DPP4i and sulfonylureas, but not versus SGLT2i.
- The analysis utilized a rigorous causal inference approach based on clinical and claims data from multiple US health-care systems.
AI simplified
Key numbers
-0.013
Adjusted Risk Difference ( vs. )
Risk difference at 2.5 years with 95% confidence interval.
-0.016
Adjusted Risk Difference ( vs. )
Risk difference at 2.5 years with 95% confidence interval.
-0.001
Adjusted Risk Difference ( vs. )
Risk difference at 2.5 years with 95% confidence interval.